Scarica l'app Stockscreener
3.06
1.32%
0.04
Dopo l'orario di chiusura:
3.02
-0.04
-1.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
MSN Money - MSN
Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com
Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan
Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan
Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan
Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan
Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan
Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan
[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan
Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan
RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan
Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan
Dilution fears return: Why ALT stock is getting hit again - MSN
ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan
ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView
Altimmune a new buy at Truist on pemvidutide promise - MSN
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union
Altimmune catalysts: 2026 data readouts and financing risks - MSN
Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter
Altimmune closes $225M financing for MASH drug trial - Investing.com UK
Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals
Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz
Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail
Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan
Altimmune prices $75M direct offering - MSN
Altimmune shares slide after $75 million registered direct offering - MSN
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):